HDL-cholesterol or apolipoprotein AI: How to choose?

被引:0
|
作者
BigotCorbel, E [1 ]
AmoryTouz, MC [1 ]
Mainard, F [1 ]
机构
[1] FAC PHARM,SERV BIOCHIM PHARMACEUT,F-44035 NANTES,FRANCE
关键词
HDL-cholesterol; apolipoprotein AI;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The French Consensus for cholesterol, established by ARCOL in 1989, recommends the use of HDL-cholesterol and apolipoprotein Al as additional parameters. The present study was undertaken to establish the correlation between these Two parameters and to determine the limit value for apolipoprotein AI, based on the recommended limit of 0.90 mmol/L for HDL-cholesterol established by ARCOL. The correlation between HDL-cholesterol analysed by precipitation, and apolipoprotein AI analysed by immunonephelemetry on the day of blood drawing, determined on 1980 samples, raised a r value of 0.89. Using the regression line equation (y = 0.602 x + 0.629), the apoliporotein AI value corresponding to the recommended HDL-cholesterol limit (0.90 mmol/L) was found to be 1.17 g/L, while the limit value established by ARCOL was 1.20 g/L. Using the HDL-cholesterol value of 0.90 mmol/L, the population was divided into a high risk group and a low risk group. With the limit value of 1.20 g/L for apolipoprotein AI, 89.2% of the subjects would be correctly classified. This percentage would be raised to 90.65% using the value (1.17 g/L) established in our study. Our conclusion is that apolipoprotein AI as well as HDL-cholesterol represent good markers for atherosclerosis in the clinical practice. The advantage of HDL-cholesterol is that the determination of this parameter allows the calculation of LDL-cholesterol which is used in all consensus, while the advantage of apolipoprotein AI is that it may be analysed automatically.
引用
收藏
页码:349 / 352
页数:4
相关论文
共 50 条
  • [31] HDL-CHOLESTEROL ON THE REFLOTRON SYSTEM
    HILLER, G
    DENEKE, J
    RITTERSDORF, W
    PLUMERWILK, R
    CLINICAL CHEMISTRY, 1987, 33 (06) : 895 - 896
  • [32] ACCURACY OF HDL-CHOLESTEROL DETERMINATION
    NIEDMANN, PD
    LUTHE, H
    WIELAND, H
    SCHAPER, G
    SEIDEL, D
    KLINISCHE WOCHENSCHRIFT, 1983, 61 (03): : 133 - 138
  • [33] The complexity of the role of HDL-cholesterol
    Brotons, Carlos
    Moral, Irene
    Vicuna, Johanna
    REVISTA ESPANOLA DE CARDIOLOGIA, 2023, 76 (02): : 78 - 79
  • [34] SERUM PSEUDOCHOLINESTERASE AND HDL-CHOLESTEROL
    PUHAKAINEN, E
    RYHANEN, R
    PENTTILA, I
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1980, 18 (10): : 684 - 684
  • [35] CIMETIDINE, RANITIDINE AND HDL-CHOLESTEROL
    WILSON, JA
    CRAIG, IF
    GASTROENTEROLOGY, 1985, 88 (05) : 1632 - 1632
  • [36] HDL-cholesterol in hypertension and diabetes
    McFarlane-Anderson, N
    Bennett, F
    Wilks, R
    Forrester, T
    Cruickshank, K
    FASEB JOURNAL, 1999, 13 (04): : A272 - A272
  • [37] CordyMax reduces serum oxidized LDL-cholesterol and increases HDL-cholesterol in humans with reduced HDL-cholesterol
    Zhu, JS
    Pei, Y
    Xu, ZB
    Wang, BE
    Rippe, J
    CIRCULATION, 2003, 108 (17) : 781 - 781
  • [38] DETERMINANTS OF HDL-CHOLESTEROL AND THE HDL-CHOLESTEROL TOTAL CHOLESTEROL RATIO - RESULTS OF THE LUBECK BLOOD-PRESSURE STUDY
    CHAMBLESS, L
    DORING, A
    FILIPIAK, B
    KEIL, U
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1990, 19 (03) : 578 - 585
  • [39] SERUM-CHOLESTEROL AND HDL-CHOLESTEROL IN CHILDHOOD
    KELLY, DA
    HOOEY, H
    NEALE, G
    MCGILL, AR
    STUART, M
    IRISH JOURNAL OF MEDICAL SCIENCE, 1981, 150 (07) : 213 - 217
  • [40] INFLUENCE OF BEZAFIBRATE AND COLESTIPOL ON LDL-CHOLESTEROL, LDL-APOLIPOPROTEIN-B AND HDL-CHOLESTEROL IN HYPERLIPOPROTEINEMIA
    KLOSIEWICZLATOSZEK, L
    NOWICKA, G
    SZOSTAK, WB
    NARUSZEWICZ, M
    ATHEROSCLEROSIS, 1987, 63 (2-3) : 203 - 209